Upstream Bio (UPB) Consolidated Net Income (2023 - 2026)

Upstream Bio has reported Consolidated Net Income for 4 years, with the latest figure at -$40.6 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 48.74% year-over-year to -$40.6 million; the trailing twelve-month figure through Mar 2026 stood at -$156.7 million (down 97.97% YoY), and the FY2025 full-year result was -$143.4 million, down 118.5% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$40.6 million, up from -$42.5 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$7.9 million in Q3 2023, with the low at -$42.5 million in Q4 2025.
• Average Consolidated Net Income over 4 years is -$24.6 million, with a median of -$21.2 million recorded in 2024.
• Year-over-year, Consolidated Net Income sank 172.22% in 2025 and sank 48.74% in 2026.
• Tracing UPB's Consolidated Net Income over 4 years: stood at -$12.8 million in 2023, then slumped by 65.81% to -$21.2 million in 2024, then slumped by 100.14% to -$42.5 million in 2025, then increased by 4.59% to -$40.6 million in 2026.
• The last three Consolidated Net Income figures came in at -$40.6 million (Q1 2026), -$42.5 million (Q4 2025), and -$33.7 million (Q3 2025), per Business Quant data.

Peer Comparison